Overview of European pilot study of interferon -1b in primary progressive multiple sclerosis

Publisher Website
Google Scholar
Abstract
This short monograph describes a trial of interferon β- 1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon β-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon β-1b in the MSFC score, T2 lesion volume and T1 lesion volume at 24 months were observed. Further study of interferon β-1b therapy in PPMS patients is warranted. Multiple Sclerosis (2004) 10, S62-S64

This publication has 0 references indexed in Scilit: